Searchable abstracts of presentations at key conferences in endocrinology

ea0010p19 | Clinical case reports/Governance | SFE2005

Informed consent for thyroxine replacement?

Gannon D , Ulahannan T

A 45 year old female with Type 1 DM for 12 years presented with malaise and frequent episodes of hypoglycaemia. Thyroxine was titrated to 150 mcg once daily over 2 months because TSH was 94 mIU/L [0.2–5.50 mIU/L]. However, her malaise and hypoglycaemia deteriorated, she also developed dense hyperpigmentation in the skin.Primary hypoadrenalism was confirmed by lack of response to 250 mcg IV Tetracosactide (Serum Cortisol at Time 0 min: 98 nmol/L; Ti...

ea0009p209 | Clinical | BES2005

Late change in immunohistochemical staining in a non-functioning pituitary adenoma following treatment with GnRH analogue

Gannon D , Nelson R , Moss T , Ulahannan T

A 64 year old man presented in 1992 with a dense bitemporal hemianopia and no endocrine symptoms. CT showed a large pituitary adenoma with suprasellar extension. He underwent transphenoidal resection of the tumour. Histology showed a typical chromophobe adenoma with no immunohistochemical staining. His vision recovered.He was followed regularly with serial MRI scan. No change was seen in the size of the residual intrasellar tumour. Pituitary testing show...

ea0003p301 | Thyroid | BES2002

Telephone follow-up following radioiodine therapy for thyrotoxicosis improves outcome

Murphy E , Mehta S , Gannon D , Bassett J , Frank J , Meeran K

In August 1999, to reduce pressure on an overcrowded outpatient department and the incidence of undetected early hypothyroidism, we implemented a new protocol for the follow-up of patients undergoing radioiodine treatment for recurrent thyrotoxicosis. Suitable patients are invited to participate in follow-up by telephone. Thyroid function tests are checked at 3, 6, 9 and 12 weeks post-treatment. Patients who become hypothyroid post-treatment (fT4 <14 picomoles per litre) a...